Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) target, is showing promising results in preliminary clinical trials . Current examination https://agendabookmarks.com/story21299473/retatrutide-emerging-investigations-and-possible-medical-roles